Back to Search
Start Over
A Facile Platform to Engineer Escherichia coli Tyrosyl-tRNA Synthetase Adds New Chemistries to the Eukaryotic Genetic Code, Including a Phosphotyrosine Mimic.
- Source :
-
ACS central science [ACS Cent Sci] 2022 Apr 27; Vol. 8 (4), pp. 483-492. Date of Electronic Publication: 2022 Mar 30. - Publication Year :
- 2022
-
Abstract
- The Escherichia coli tyrosyl-tRNA synthetase (EcTyrRS)/tRNA <superscript>EcTyr</superscript> pair offers an attractive platform for genetically encoding new noncanonical amino acids (ncAA) in eukaryotes. However, challenges associated with a eukaryotic selection system, which is needed to engineer the platform, have impeded its success in the past. Recently, using a facile E. coli -based selection system, we showed that EcTyrRS could be engineered in a strain where the endogenous tyrosyl pair was substituted with an archaeal counterpart. However, significant cross-reactivity between the UAG-suppressing tRNA <subscript>CUA</subscript> <superscript>EcTyr</superscript> and the bacterial glutaminyl-tRNA synthetase limited the scope of this strategy, preventing the selection of moderately active EcTyrRS mutants. Here we report an engineered tRNA <subscript>CUA</subscript> <superscript>EcTyr</superscript> that overcomes this cross-reactivity. Optimized selection systems based on this tRNA enabled the efficient enrichment of both strongly and weakly active ncAA-selective EcTyrRS mutants. We also developed a wide dynamic range (WiDR) antibiotic selection to further enhance the activities of the weaker first-generation EcTyrRS mutants. We demonstrated the utility of our platform by developing several new EcTyrRS mutants that efficiently incorporated useful ncAAs in mammalian cells, including photoaffinity probes, bioconjugation handles, and a nonhydrolyzable mimic of phosphotyrosine.<br />Competing Interests: The authors declare the following competing financial interest(s): A patent application on the EcTyrRS mutants and ncAAs reported here has been submitted. A.C. is a cofounder and senior advisor of BrickBio, Inc., which focuses on applications of the ncAA mutagenesis technology.<br /> (© 2022 The Authors. Published by American Chemical Society.)
Details
- Language :
- English
- ISSN :
- 2374-7943
- Volume :
- 8
- Issue :
- 4
- Database :
- MEDLINE
- Journal :
- ACS central science
- Publication Type :
- Academic Journal
- Accession number :
- 35559426
- Full Text :
- https://doi.org/10.1021/acscentsci.1c01465